MARATTO

article · african journal of gastroenterology and hepatology

The influence of lncRNA expression dysregulation on predicting celiac diseases among patients with Hashimoto's thyroiditis

2024Open accessZagazig University

Abstract

Aim: the study aimed to investigate lncRNA IFNG-AS1 in Hashimoto’s thyroiditis (HT) and to evaluate its predictive and diagnostic values of Celiac disease (CD) among patients with HT. Patients and Methods One hundred voluntary subjects: 50 healthy controls and 50 patients with HT;39 without CD and 11 with CD. Routine labs, including anti-TG, anti-TPO, and anti-TTG-IgA, investigated all subjects. lncRNA IFNG-AS1 expression was analyzed using Quantitative real-time RT-PCR.ResultsPatients with CD had significantly overexpressed lncRNA IFNG-AS1(4.17±0.618) compared to patients without CD (1.92±0.52) and control group (0.98±0.21), p ˂0.001*. It correlated considerably with intestinal and extra-intestinal manifestations and laboratory tests, including anti-TG, anti-TPO, and TTG IgA. Multivariate regression confirmed that the only variables independently associated with lncRNA IFNG-AS1 in the prediction of CD among studied parameters were anti-TG, anti-TPO, and TTG IgA. We found high sensitivity and specificity of 96% and 94% among HT, respectively. Concerning CD, the predictive power of IFNG-AS1 had sensitivity and specificity of 63.3% and 53%, respectively.Conclusion: lncRNA IFNG-AS1 level was overexpressed in patients with HT, particularly those with CD, and correlated to clinical and laboratory parameters. Accordingly, it may be a promising predictive biomarker for HT and CD.

Research topics

  • Celiac Disease Research and Management

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/ajgh.2024.262342.1048

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.